51 results about "Interleukin 11" patented technology

Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.

The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed.

The invention provides compositions containing polypeptides, including therapeutic polypeptides such as interleukin-11, that are suitable for oral administration.

The present invention demonstrates the myocardial protective effects of interleukin 11 in vivo, and provides preventive, therapeutic, or other types of drugs for heart disease using interleukin 11 as the active ingredient. The present invention, by utilizing the myocardial protective effects of interleukin 11, can suppress the progress of myocardial injury, prevent the onset of heart failure, or suppress the progress of heart failure.

The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed.

The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures.

The invention relates to a porcine interleukin 11, and a purpose of the porcine interleukin 11 in resisting porcine epidemic diarrhea virus infection. After porcine epidemic diarrhea virus infection happens, a piglet intestinal tract secretes cell factor porcine pIL-11 which is obviously improved, and the expression of the cell factor exhibits high correlation with a virus infection level. The invention discloses a prokaryotic expression plasmid for constructing a recombinant pIL-11, a transformed escherichia coli BL21, and a specific method for obtaining a high-purity recombinant pIL-11 through purification. The recombinant pIL-11 can inhibit the infection of the PEDV (Porcine epidemic diarrhea virus) for a host cell, and has obvious dose dependency. The recombinant pIL-11 activates a STAT3 (signal transducer and activator of transcription 3) signal to inhibit host cell apoptosis induced after PEDV infection happens so as to perform a function of resisting virus infection. The porcinesource IL-11 has a function of resisting virus infection and alleviating piglet intestinal tract injury, and is expected to become an effective medicine for resisting PEDV intestinal tract infectionin the future.

The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit essentially no loss of activity as compared to the corresponding unconjugated mIL-11.

The invention provides a composition for regulating enteric microorganisms. The composition comprises solvent and components, such as, by weight, 50-500ng / mL of stem cell growth factor, 500-5000 U / mL of human interferon-Lambda, 500-5000 U / mL of human interleukin 2, 50-1000 U / mL of human interleukin 11, 1-10 mu g / mL of folium artemisiae argyi extractive, and 1vol%-3vol% of human plasma albumin solution. Through synergistic effect of the stem cell growth factor, the human interferon-Lambda, the human interleukin 2, the human interleukin 11, the human plasma albumin solution and the folium artemisiae argyi extractive, the composition can improve the whole immune system of a human body and strengthen the killing and removing ability of own immune cell to harmful flora; meanwhile, the composition can effectively regulate the intestinal microflora, increase probiotics, reduce harmful bacteria, and maintain a healthy environment of the whole intestinal canal.

Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis, and infectious colitis), mucositis (e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (e.g., psoriasis, atopic dermatitis, and contact hypersensitivity), aphthous ulcers, pharyngitis, esophagitis, peptic ulcers, gingivitis, periodontitis, and ocular diseases (e.g., conjunctivitis, retinitis, and uveitis).

Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or anti-inflammatory properties, fused to albumin (including, but not limited to, fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and / or pharmacokinetic properties and / or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and / or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.